Biology to Therapy in the Bone Marrow Niche

Part of the Oncology Grand Rounds Series - David Scadden, MD, Department of Stem Cell and Regenerative Biology at Harvard University, identifies new approaches to improve hematopoietic stem cell (HSC) mobilization and non-genotoxic methods of patient conditioning for HSC transplantation. Dr. Scadden also defines stroll cell components that guide T cell production and how they can be used to enhance immune reconstitution after HSC transplantation. 


Created by

Johns Hopkins Greater Washington Area